---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-057256"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:34:13.643075+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharma Q1 net loss $2.6M; cash $17M; first patient dosed in Netherton trial

## Summary
- Net loss $2.6M for Q1 2023 vs $1.7M in Q1 2022; cash & equivalents $17.0M as of March 31, 2023.
- First patient dosed in open-label trial of QRX003 for Netherton Syndrome patients on off-label systemic therapy.
- Recruiting and dosing continue in double-blinded, placebo-controlled study of QRX003 for Netherton Syndrome.
- Completed public offering in Feb 2023 with net proceeds ~$5.8M, extending cash runway into 2H 2024.
- Two rare disease programs with Queensland University of Technology; expect clinical testing in Australia in 2H 2023.

## SEC filing metadata
- accession: 0001104659-23-057256
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465923057256/0001104659-23-057256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465923057256/tm2314978d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-057256
- JSON: https://secwatch.observer/filing/0001104659-23-057256.json
- Plain text: https://secwatch.observer/filing/0001104659-23-057256.txt

## Key facts
- Earnings Releases
  Quoin Pharmaceuticals, Ltd. reported the first quarter of 2023 results: net income approximately $2.6 million.
  - Period: the first quarter of 2023
  - Net income: approximately $2.6 million
  - Result: reported results
  source text: Net loss for the quarter ended March 31, 2023 was approximately $2.6 million compared to approximately $1.7 million for the quarter ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923057256/0001104659-23-057256-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.